PROUD OF ITS PAST, FOCUSED ON THE FUTURE
The Institut Jules Bordet, which initially consisted of a surgical and a radiotherapy department, was established in 1939. The Institute started to expand considerably after the Second World War.
spirit of innovation Following the impetus of Professors Albert Claude and Henri Tagnon after their respective returns from the United States in the early 1950s, the Institute rapidly developed innovative activities: a depart- ment of medicine with speciﬁc sectors for chemotherapy and immunotherapy; pathology and nuclear medicine laboratories; and new medical imaging techniques. Already at this time, the ideas of approaching cancer treatment and care in a multidisciplinary man- ner and integrating research and teaching into treatment had taken shape. Since then, the Institute has continued to participate actively in the development of new diagnostic, therapeutic and preventive techniques, which are quickly made available to the public.
Some examples of this innovation include the following: 1953, creation of a research laboratory in the Department of Medicine 1964, opening of a screening clinic 1972, inauguration of the ﬁrst oncological “day hospital” for chemo- therapy in Belgium
1975, the ﬁrst autologous transplantation of haematopoietic stem cells and the development of a new method for measuring oes- trogen receptors in breast cancers
1978, convening the ﬁrst hospital ethics committee in Belgium 1985, establishment of the ﬁrst Psycho-Oncology Unit and Breast Clinic in the country
1989, creation of a training course in oncology for nurses and establishment of a rehabilitation unit
1990, ﬁrst developments in translational research and the com- mencement of a programme for giving up smoking
1994, set-up of the ﬁrst Belgian cord blood bank 1997, introduction of the sentinel lymph node surgical technique 1999, ﬁrst haploidentical haematopoietic stem cell transplanta- tion in the world and ﬁrst laparoscopic radical prostatectomy in Belgium
2004, ﬁrst treatment of hepatic metastases with radioactive microspheres in Belgium
2006, development of the Genomic Grade Index, a genomic sig- nature making it possible to predict the aggressiveness of breast cancers to help determine the best treatment options
2009, establishment of intraoperative radiotherapy with Mobetron
F or over 70 years, the Institut Jules Bordet has been providing its patients – and the general public – with a wide range of state-of-the-art strategies for dealing with cancer. The Insti- tute, which is an academic one, combines three essential mis- sions: treatment, research and teaching. Its international rep- utation draws many talented people to the Institute, who discover an environment con- ducive to fulﬁlling their human and professional qualities.